Kohei Shitara, MD: Fam-Trastuzumab Deruxtecan-Nxki for Gastric Cancer

Fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo) has recently been FDA approved for the treatment of adult patients with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal adenocarcinoma previously treated with a trastuzumab-based regimen. In this interview with i3 Health, Kohei Shitara, MD, Chief of the Department of Gastrointestinal Oncology at the National Cancer Center Hospital East in Kashiwa, Japan, and lead investi...
Continue reading

PD-L1–Positive Gastric Cancer: Frontline Pembrolizumab Noninferior to Chemotherapy

Data from the phase 3 KEYNOTE-062 trial have revealed that in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer with a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or greater, first-line pembrolizumab, alone or in combination with chemotherapy, is noninferior but not superior to chemotherapy alone. In patients with a PD-L1 CPS of 10 or greater, pembrolizumab monotherapy showed a possible benefit, but one that cannot be considered definitive o...
Continue reading

Heavily Pretreated Metastatic Gastric Cancer: Dr. Kohei Shitara on Trifluridine/Tipiracil Approval

The FDA's recent approval of trifluridine/tipiracil tablets (Lonsurf®, Taiho Pharmaceutical Co., Ltd.) for heavily pretreated metastatic gastric adenocarcinoma and gastroesophageal junction adenocarcinoma represents a significant development for patients with gastric cancer, the third most frequent cause of cancer-related death. In this interview with i3 Health, Kohei Shitara, MD, speaks about the significance of this approval. Dr. Shitara was the lead author of the phase 3 TAGS study (NCT0...
Continue reading

Trifluridine/Tipiracil Approved for Metastatic Gastric Cancer

Gastric cancer, the fifth most common cancer worldwide and the third most common cause of cancer-related death, is particularly difficult to treat because most patients present with advanced or metastatic disease. However, patients with metastatic disease now have a new treatment option through the FDA's recent approval of trifluridine/tipiracil tablets (Lonsurf®, Taiho Pharmaceutical Co., Ltd.). Trifluridine/tipiracil, a fixed combination of the nucleoside metabolic inhibitor trifluridine and t...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.

Cron Job Starts